Evaluating HMPL-453 for advanced intrahepatic cholangiocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the efficacy and safety of HMPL-453 tartrate in patients with advanced intrahepatic cholangiocarcinoma that have FGFR2 fusions or rearrangements. Participants will receive HMPL-453 orally for 14 days followed by a 7-day break, in a 21-day treatment cycle. The study includes two cohorts: one for patients with locally advanced unresectable or metastatic disease after prior treatment failure, and another for safety assessments before extending to a larger group. The primary goal is to evaluate the objective response rate in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Have fully understood the study and voluntarily signed the ICF;
2. Age ≥ 18 years;
3. a. pathologically or cytologically confirmed advanced treatment failure solid tumor with standard patients (applicable to cohorts2 stage I); b. histologically or cytologically confirmed histologically or cytologically confirmed locally advanced unresectable or metastatic ICC patients with FGFR2 fusions/rearrangements/mutation (applicable to Cohort 1, Cohort 2 Stage II, Cohort 3 and Cohort 4)
4. a. The patients have received at least one prior systemic treatment regimen for advanced ICC and has intolerable PD or toxicity(Cohort1-3); b. Patients who have not received any prior systemic therapy for advanced ICC(Cohort4)
5. Measurable lesion according to RECIST v1.1;
6. ECOG performance status of 0 or 1;
7. Life expectancy ≥ 12 weeks;
8. Female patients or male patients with partners of childbearing potential must take effective contraceptive measures per the protocol.

Exclusion Criteria:

1. Patients who previously received selective FGFR targeting therapy;
2. Received approved or researched systemic anti-tumor treatment within 3 weeks prior to the start of the study treatment;
3. Radical radiotherapy within 4 weeks;
4. Have received local anti-tumor treatment within 4 weeks;
5. Major surgery requiring hospitalization or incomplete healing of the surgery incision within 4 weeks;
6. Current or prior history of retinal detachment;
7. Using a strong inducer or inhibitor of cytochrome P450 3A (CYP3A) within 2 weeks or 5 half-lives of the study treatment;
8. Taking drugs or dietary supplementsthat may cause blood phosphorus and/or blood calcium to rise within 2 weeks prior to the start of the study treatment;
9. International normalized ratio above 1.5 or partial activated prothrombin time above 1.5 times ULN;
10. History of clinically significant active hepatopathy, including active viral hepatitis, or other active hepatitis, clinically significant moderate to severe liver cirrhosis;
11. The patients with human immunodeficiency virus (HIV) infection;
12. Active infection requiring systemic treatment within 1 week prior to the start of the study treatment;
13. Screening blood phosphorus levels above ULN, or history of abnormal calcium phosphorus metabolism requiring clinical intervention or relevant medical history;
14. Currently keratopathy confirmed by ophthalmological examination;
15. Prior history of retinal detachment, or current diseases that may cause retinal detachment;
16. Clinically significant arrhythmia or conduction abnormalities requiring clinical intervention;
17. Patients with known deep venous thrombosis, treated with low molecular weight heparin (LMWH) or drugs with similar efficacy, and the investigator judges that the thrombosis is stable for ≥ 2 weeks ;
18. Toxicities caused by prior anti-tumor treatment have not recovered to grade 0 or 1;
19. The patient has any current disease or condition that affects drug absorption, or the patient cannot be orally administered;
20. Combined with other malignant tumor or a history of other malignant tumor within 5 years prior to study screening;
21. Patients currently has central nervous system metastases, meningeal metastases or spinal cord compression, except in individual cases;
22. Any other medical condition or clinically significant laboratory abnormalities judged by the investigator would make the patients unsuitable to participate in this study.

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Jianming Xu, PhD — Chinese PLA General Hospital
• Study coordinator: Bo Zhang
• Email: boz@hutch-med.com
• Phone: +86 21 2067 1819

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HMPL-A830 in solid tumors for adults with unresectable or metastatic cancer

  This first-in-human study tests HMPL-A830 in adults with unresectable or metastatic solid tumors to see how safe it is and how it behaves at varying doses.

  Recruiting at 4 sites Phase 1/2 Hutchmed · Orange, California and 13 other locations · NCT07718581

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Personalized PULSAR radiotherapy for advanced small cell lung cancer and brain metastases

  This trial will try personalized PULSAR radiotherapy schedules to see if they are safe and helpful for adults with extensive-stage small cell lung cancer who need thoracic radiation and for adults with 1–5 brain metastases.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07139990

• VS-7375 for adults with KRAS G12D-mutated advanced solid tumors.

  This trial tests VS-7375, alone and combined with other cancer drugs, in adults with unresectable or metastatic solid tumors that have the KRAS G12D mutation.

  Recruiting at 22 sites Phase 1/2 Verastem, Inc. · Los Angeles, California and 21 other locations · NCT07020221

• Using a modified cold virus to treat certain solid tumors

  This study is testing a new treatment made from a modified cold virus to see if it can safely target and help people with certain types of solid tumors.

  Recruiting at 7 sites Phase 1/2 Accession Therapeutics Limited · Barcelona and 7 other locations · NCT06977737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.